The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Open accessAbstract
Alzheimer’s disease is the world’s most common dementing illness. Deposition of amyloid-β peptide drives cerebral neuroinflammation by activating microglia. Indeed, amyloid-β activation of the NLRP3 inflammasome in microglia is fundamental for interleukin-1β maturation and subsequent inflammatory events. However, it remains unknown whether NLRP3 activation contributes to Alzheimer’s disease in vivo. Here we demonstrate strongly enhanced active caspase-1 expression in human mild cognitive impairment and brains with Alzheimer’s disease, suggesting a role for the inflammasome in this neurodegenerative disease. Nlrp3−/− or Casp1−/− mice carrying mutations associated with familial Alzheimer’s disease were largely protected from loss of spatial memory and other sequelae associated with Alzheimer’s disease, and demonstrated reduced brain caspase-1 and interleukin-1β activation as well as enhanced amyloid-β clearance. Furthermore, NLRP3 inflammasome deficiency skewed microglial cells to an M2 phenotype and resulted in the decreased deposition of amyloid-β in the APP/PS1 model of Alzheimer’s disease. These results show an important role for the NLRP3/caspase-1 axis in the pathogenesis of Alzheimer’s disease, and suggest that NLRP3 inflammasome inhibition represents a new therapeutic intervention for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rat research has identified the NLRP3-ASC inflammasome as a major mechanism through which microglia may drive pathological features of AD [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both beta-amyloids and tau can activate the NLRP3-ASC inflammasome within microglia [92,93].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The nucleotide-binding oligomerization domain-like receptor, pyrin domain-containing 3 (NLRP3), within microglia recruits the adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase recruitment domain (ASC) to form an inflammasome complex.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In APP/PS1 mice model, NLRP3 knockout reduced Aβ deposition by enhancing phagocytic clearance capacity and increasing extracellular Aβ degradation by insulin- degrading enzyme (IDE).354”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [354]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of hippocampal NLRP3 inflammasome-mediated pyroptosis is associated with neuronal damage, cognitive decline, and neuronal death (Hanslik & Ulland, 2020; Heneka et al., 2013; Ising et al., 2019; Venegas et al., 2017).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NLRP3 or caspase-1 knockdown in AD mouse models has yielded promising results in decreasing Aβ accumulation, improving spatial memory, and alleviating other AD-related symptoms (Heneka et al., 2013).”
From Picroside II Alleviates the Progression of Alzheimer’s Disease via the NLRP3/Caspase-1/GSDMD Pathway (2025) · cites this paper as Heneka et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablation of Nlrp3 or Casp1 in APP/PS1 mice rescued spatial memory and behavioral deficits, LTP suppression and spine loss observed in these mice [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, another study reported strongly increased levels of active caspase-1 in early-onset AD and LOAD patients as well as in MCI individuals [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This inflammasome complex is responsible for the production of IL-1 beta, which is a proinflammatory cytokine.”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“IL-1 beta was shown to exacerbate tau pathologies [97] and reduce microglial phagocytic activity [92,93,94].”
From The Role of Cortisol in Chronic Stress, Neurodegenerative Diseases, and Psychological Disorders (2023) · cites this paper as [92]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, microglial function may also be of relevance to cognitive performance, as suggested by recent experimental data, which showed that improved microglial clearance was protective in terms of memory function (17).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Proinflammatory environments and signalling are a prominent observation in AD brain pathology [39].”
From Heterozygous expression of the Alzheimer’s disease-protective PLCγ2 P522R variant enhances Aβ clearance while preserving synapses (2022) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Inhibiting or downregulating the NLRP3 inflammasome ameliorates AD neuropathology in animal models, which opens up a therapeutic avenue for modulators of NLRP3 activation in AD.”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“APP/PS1/Nlrp3−/− and APP/PS1/Casp1−/− mice also displayed decreased Aβ plaque deposition, suggesting that NLRP3 inflammasome activation impairs microglial capacity to clear Aβ [77].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“The decreased plaque deposition was also related to increased levels of the proteolytic enzyme insulin-degrading enzyme (IDE) [77], previously reported to degrade Aβ [83].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“NLRP3 deficiency reduces amyloid deposition and rescues memory deficits in the APP/PS1 model of AD [18].”
From 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) · cites this paper as [18]
In the citing paper
“One of the key biological functions of CASP1 is the cleavage of prointerleukin-1β (IL-1β) into the mature biological active cytokine, which is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Preclinical studies support the concept that CASP1-directed increase of IL-1β can augment the deposition of β-amyloid within the brain to worsen Alzheimer's symptoms.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“CASP1, an essential component of NLPR3 inflammasomes, encodes a cysteine protease that is largely overexpressed in brains of patients with AD.44”
From APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer’s disease (2016) · cites this paper as [44]
In the citing paper
“Notably, Aβ also can activate NF-κB signaling and the NLRP3-ASC inflammasome [426, 427], suggesting that Aβ and tau share common mechanisms in microglia activation.”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [427]
In the citing paper
“The NLRP3 inflammasome is critical for maturation of IL-1β, and loss of NLRP3 in APP/PS1 decreased amyloid burden (131).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [131]
In the citing paper
“Microglia express multiple receptors that can bind Aβ and trigger inflammation, such as CD36 (105), TLR2, TLR4, TLR6 (17), and NLRP3 (106)”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [106]
In the citing paper
“NLRP3 and caspase-1 genetic deletion results in decreased Aβ deposition, reduced IL-1β release from microglia and improved cognitive performance in APPPS1 mice (Heneka et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Toll-like receptors and NOD-like receptors have been previously implicated in the microglia response to Aβ accumulation and shown to mediate an inflammatory response that contributes to pathology”
From TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017) · cites this paper as Heneka et al., 2013
In the citing paper
“ITGAM/CD11b (or CR3A), is a cell surface receptor involved in activation, migration and phagocytosis of immune cells, so much so that ITGAM/CD11b is used as a marker of activated microglia (Matsuoka et al., 2001; Heneka et al., 2013; Kamphuis et al., 2016).”
From Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk (2019) · cites this paper as Heneka et al., 2013
In the citing paper
“Animal studies confirmed this significant involvement of NLRP activation, as APP/PS1 mice, lacking the expression of ASC, caspase-1, or NLRP3 had significantly reduced hippocampal and cortical amyloid plaque deposition and ameliorated disease outcome (229, 230).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [230]
In the citing paper
“Recently, an alternative pathway has been described for intracellular signaling produced by the binding of Aβ to microglial cells, activating NLRP3 inflammasome (Heneka et al., 2013; Sheedy et al., 2013).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Heneka et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Self-citationThe Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C. G., McDowell, J., Paskind, M. P., Rodman, L., Salfeld, J. G., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90490-5 · Cited by 1,408
Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 1×
“Cytokines, including IL-1 β , were found to impair microglial clearance functions 16,17 .”
Bevins, R. A., & Besheer, J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.205 · Cited by 1,278
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3
Kanneganti, T., Özören, N., Body–Malapel, M., Amer, A. O., Park, J., Franchi, L., Whitfield, J. R., Barchet, W., Colonna, M., Vandenabeele, P., et al. (2006) · Nature · doi:10.1038/nature04517 · Cited by 1,149
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Flagged first, then by citations
2 of the 34 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,031
Inflammasomes: Key Mediators of Lung Immunity
Howrylak, J. A., & Nakahira, K. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105229 · Cited by 67
Impact of Morphology on Iron Oxide Nanoparticles-Induced Inflammasome Activation in Macrophages
Liu, L., Sha, R., Yang, L., Zhao, X., Zhu, Y., Gao, J., Zhang, Y., & Wen, L. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b17474 · Cited by 65
Böhm, C., Chen, F., Sévalle, J., Qamar, S., Dodd, R. B., Li, Y., Schmitt‐Ulms, G., Fraser, P. E., & George‐Hyslop, P. S. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.016 · Cited by 66
Positive Feedback Loops in Alzheimer’s Disease: The Alzheimer’s Feedback Hypothesis
Doig, A. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180583 · Cited by 67
Can We Treat Neuroinflammation in Alzheimer’s Disease?
Sánchez‐Sarasúa, S., Fernández-Pérez, I., Espinosa‐Fernández, V., Sánchez‐Pérez, A. M., & Ledesma, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228751 · Cited by 64
Targeting Microglia-Synapse Interactions in Alzheimer’s Disease
Piccioni, G., Mango, D., Saidi, A., Corbo, M., & Nisticò, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052342 · Cited by 64
Budden, C. F., Gearing, L. J., Kaiser, R., Standke, L., Hertzog, P. J., & Latz, E. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12127 · Cited by 66
Self-citationDuan, R., Wang, S.-Y., Wei, B., Deng, Y., Fu, X.-X., Gong, P.-Y., Yan, E., Sun, X.-J., Cao, H.-M., Shi, J.-Q., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s343575 · Cited by 64
Ferroptosis, Pyroptosis, and Cuproptosis in Alzheimer’s Disease
Wang, Q., Sun, J., Chen, T., Song, S., Hou, Y., Feng, L., Fan, C., & Li, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00343 · Cited by 65
Son, S., Hwang, I., Han, S. H., Shin, J., Shin, O. S., & Yu, J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.806307 · Cited by 64
Jeon, S.-A., Lee, E., Hwang, I., Han, B., Park, S., Son, S., Yang, J., Hong, S., Kim, C. H., Son, J., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx065 · Cited by 62
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
Sim, A. Y., Barua, S., Kim, J. Y., Lee, Y.-H., & Lee, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708547 · Cited by 62
African ancestry GWAS of dementia in a large military cohort identifies significant risk loci
Sherva, R., Zhang, R., Sahelijo, N., Jun, G., Anglin, T., Chanfreau, C., Cho, K., Fonda, J. R., Gaziano, J. M., Harrington, K. M., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01890-3 · Cited by 68
Filiou, M. D., Arefin, A. S., Moscato, P., & Graeber, M. B. (2014) · Neurogenetics · doi:10.1007/s10048-014-0409-x · Cited by 62
Love and death: microglia, NLRP3 and the Alzheimer's brain
Goldmann, T., Tay, T. L., & Prinz, M. (2013) · Cell Research · doi:10.1038/cr.2013.24 · Cited by 63
Hishimoto, A., Pletnikova, O., Lang, D. L., Troncoso, J. C., Egan, J. M., & Liu, Q.-R. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0475-2 · Cited by 62
Reformulating Pro-Oxidant Microglia in Neurodegeneration
García‐Revilla, J., Alonso-Bellido, I. M., Burguillos, M. Á., Herrera, A. J., Espinosa‐Oliva, A. M., Ruiz, R., Cruz-Hernández, L., García-Domínguez, I., Roca-Ceballos, M. A., Santiago, M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101719 · Cited by 66
Microglial Function and Regulation during Development, Homeostasis and Alzheimer’s Disease
Casali, B. T., & Reed-Geaghan, E. G. (2021) · Cells · doi:10.3390/cells10040957 · Cited by 70
ER stress associated TXNIP-NLRP3 inflammasome activation in hippocampus of human Alzheimer's disease
Ismael, S., Wajidunnisa, Sakata, K., McDonald, M. P., Liao, F., & Ishrat, T. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105104 · Cited by 62
Barrios, L. C., Pinheiro, A. P. D. S., Gibaldi, D., Silva, A. A., Silva, P., Roffê, E., Santiago, H. C., Gazzinelli, R. T., Mineo, J. R., Silva, N. M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258199 · Cited by 63
Jiao, Y., Nan, J., Mu, B., Zhang, Y., Zhou, N., Yang, S., Zhang, S., Lin, W.-T., Wang, F., Xia, A., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114194 · Cited by 61
Kim, S., Kim, D. K., Jeong, S., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115894 · Cited by 71
Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 68
Wang, M., Tang, G., Zhou, C., Guo, H., Hu, Z., Hu, Q., & Li, G. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110387 · Cited by 62
Zhang, H., Peng, J., Cheng, X.-B., Shi, B., Zhang, M., & Xu, R. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1632-z · Cited by 62
The role of inflammation and interleukin-1 in acute cerebrovascular disease
Brough, D., & Galea, J. P. (2013) · Journal of Inflammation Research · doi:10.2147/jir.s35629 · Cited by 63
FTY720 Inhibits MPP+-Induced Microglial Activation by Affecting NLRP3 Inflammasome Activation
Yao, S., Li, L., Sun, X., Hua, J., Zhang, K., Hao, L., Liu, L., Shi, D., & Zhou, H. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09843-4 · Cited by 62
Apelin/APJ system: A novel promising target for neurodegenerative diseases
Luo, H., Han, L., & Xu, J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29001 · Cited by 61
Manji, Z., Rojas, A., Wang, W., Dingledine, R. J., Varvel, N. H., & Ganesh, T. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180678 · Cited by 65
Fu, Q., Li, J., Qiu, L., Ruan, J., Mao, M., Li, S., & Mao, Q.-H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106317 · Cited by 61
Role of Neuron and Glia in Alzheimer’s Disease and Associated Vascular Dysfunction
Bandyopadhyay, S. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.653334 · Cited by 64
Chiu, Y., Lin, C., Lee, M.-C., Hsieh‐Li, H. M., Chen, C., Wu, Y., Chang, K., & Lee‐Chen, G. (2021) · Aging · doi:10.18632/aging.203125 · Cited by 61
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms
Chen, F., Chen, Y., Wang, Y., Ke, Q., & Cui, L. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00316-y · Cited by 63
Chen, P., Han, X., Shaw, T. I., Fu, Y., Sun, H., Niu, M., Wang, Z., Jiao, Y., Teubner, B. J. W., Eddins, D. M., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00290-0 · Cited by 60
Loss of function of CMPK2 causes mitochondria deficiency and brain calcification
Zhao, M., Su, H., Zeng, Y., Sun, Y., Guo, X.-X., Li, Y., Wang, C., Zhao, Z., Xue-jing, H., Lin, K.-J., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00475-2 · Cited by 64
Qiu, Y., Shen, X., Ravid, O., Atrakchi, D., Rand, D., Wight, A. E., Kim, H.-J., Zaltsman, S. L., Cooper, I., Beeri, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218915120 · Cited by 62
Choi, S.-B., Kwon, S., Kim, J.-H., Ahn, N.-H., Lee, J.-H., & Yang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411757 · Cited by 65
Al-Khazaleh, A. K., Zhou, X., Bhuyan, D. J., Münch, G. W., Al-Dalabeeh, E. A., Jaye, K. M., & Chang, D. (2024) · Molecules · doi:10.3390/molecules29020410 · Cited by 66
Li, H., Cai, R., Zhou, Y., Jiang, Y., & Tan, S. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03563-8 · Cited by 72
GPCRs in NLRP3 Inflammasome Activation, Regulation, and Therapeutics
Tang, T., Gong, T., Jiang, W., & Zhou, R. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.002 · Cited by 64
Visceral adiposity, inflammation, and hippocampal function in obesity
Stranahan, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108920 · Cited by 63
Alzheimer's disease as an innate autoimmune disease (AD 2 ): A new molecular paradigm
Weaver, D. F. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12789 · Cited by 68
Chiarini, A., Gui, L., Viviani, C., Armato, U., & Prà, I. D. (2023) · Biomedicines · doi:10.3390/biomedicines11040999 · Cited by 62
Microglial response to aging and neuroinflammation in the development of neurodegenerative diseases
Han, T., Xu, Y., Sun, L., Hashimoto, M., & Wei, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385845 · Cited by 64
Wang, Z., Liu, J., Han, J., Zhang, T., Li, S., Hou, Y., Su, H., Han, F., & Zhang, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03166-9 · Cited by 60
The Role of Glial Cell Senescence in Alzheimer's Disease
Alshaebi, F., Sciortino, A., & Kayed, R. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70051 · Cited by 60
Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease
Sawada, H., Oeda, T., Umemura, A., Tomita, S., Kohsaka, M., Park, K., Yamamoto, K., & Sugiyama, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134118 · Cited by 60
Lynch, M. A. (2013) · Immunology · doi:10.1111/imm.12156 · Cited by 64
Impact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 64
Lee, J., Kim, H., Kim, J., Yook, T. H., Kim, K. H., Lee, J. Y., & Yang, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031324 · Cited by 61
Pyroptosis: A promising therapeutic target for noninfectious diseases
Li, T., Zheng, G., Li, B., & Tang, L. (2021) · Cell Proliferation · doi:10.1111/cpr.13137 · Cited by 60
Flores, J., Noël, A., Fillion, M.-L., & LeBlanc, A. C. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00881-1 · Cited by 59
Tan, S.-W., Zhao, Y., Li, P., Ning, Y., Huang, Z.-Z., Yang, N., Liu, D., & Zhou, Y. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02274-0 · Cited by 59
Kinra, M., Nampoothiri, M., Arora, D. S., & Mudgal, J. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13124 · Cited by 60
Inflammasome Signaling in the Aging Brain and Age-Related Neurodegenerative Diseases
Brahadeeswaran, S., Sivagurunathan, N., & Latchoumycandane, C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02683-5 · Cited by 63
Hulse, J. P., & Bhaskar, K. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.805169 · Cited by 63
Bahri, F., Mansoori, M., Vafaei, S., Fooladi, S., Mir, Y., Mehrabani, M., Hozhabri, Y., Nematollahi, M. H., & Iravani, S. (2024) · Materials Advances · doi:10.1039/d3ma00856h · Cited by 63
Sulforaphane attenuates activation of NLRP3 and NLRC4 inflammasomes but not AIM2 inflammasome
Lee, J., Ahn, H., Hong, E., An, B., Jeung, E., & Lee, G. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.07.007 · Cited by 59
Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation
Yu, X., Zhao, Q., Zhang, X., Zhang, H., Liu, Y., Wu, X., Li, M., Li, X., Zhang, J., Ruan, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18619 · Cited by 60
Stavudine Reduces NLRP3 Inflammasome Activation and Modulates Amyloid-β Autophagy
Rosa, F. L., Saresella, M., Marventano, I., Piancone, F., Ripamonti, E., Al‐Daghri, N. M., Bazzini, C., Zoia, C., Conti, E., Ferrarese, C., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181259 · Cited by 61
A role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance
Zhang, H., Chen, W., Tan, Z., Zhang, L., Dong, Z., Cui, W., Zhao, K., Wang, H., Jing, H., Cao, R., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0250-20.2020 · Cited by 58
The microbiome and cytosolic innate immune receptors
Liwinski, T., Zheng, D., & Elinav, E. (2020) · Immunological Reviews · doi:10.1111/imr.12901 · Cited by 61
Targeting NLRP3 Inflammasome in Translational Treatment of Nervous System Diseases: An Update
Yu, Q., Zhao, T., Liu, M., Cao, D., Li, J., Li, Y., Xia, M., Wang, X., Zheng, T., Liu, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.707696 · Cited by 61
Myeloid Cells in Alzheimer's Disease: Culprits, Victims or Innocent Bystanders?
Meyer‐Luehmann, M., & Prinz, M. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.011 · Cited by 58
The rOX‐stars of inflammation: links between the inflammasome and mitochondrial meltdown
Holley, C. L., & Schroder, K. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1109 · Cited by 61
Emerging role of microRNAs in ischemic stroke with comorbidities
Yu, Q., Chopp, M., & Chen, J. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113382 · Cited by 58
Target Dysbiosis of Gut Microbes as a Future Therapeutic Manipulation in Alzheimer’s Disease
Zhu, F., Li, C., Chu, F., Tian, X., & Zhu, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.544235 · Cited by 59
Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
Calvo-Rodríguez, M., Kharitonova, E. K., & Bacskai, B. J. (2020) · Cells · doi:10.3390/cells9112513 · Cited by 60
Fernando, K., & Wijayasinghe, Y. S. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.746631 · Cited by 57
Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis
Gabillard-Lefort, C., Casey, M., Glasgow, A. M. A., Boland, F., Kerr, O., Marron, E., Lyons, A. M., Gunaratnam, C., McElvaney, N. G., & Reeves, E. P. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202106-1426oc · Cited by 57
Schoor, E. V., Ospitalieri, S., Moonen, S., Tomé, S. O., Ronisz, A., Ok, O., Weishaupt, J. H., Ludolph, A. C., Damme, P. V., Bosch, L. V. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02466-9 · Cited by 64
Interaction between autophagy and the NLRP3 inflammasome in Alzheimer’s and Parkinson’s disease
Lu, R., Zhang, L., & Yang, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1018848 · Cited by 58
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors
Xu, Y., Yang, Y., Chen, X., Jiang, D., Zhang, F., Guo, Y., Hu, B., Xu, G., Peng, S., Wu, L., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00381-x · Cited by 65
Epigenetic Regulation of Neuroinflammation in Alzheimer’s Disease
Ma, Y., Wang, W., Liu, S., Qiao, X., Xing, Y., Zhou, Q., & Zhang, Z. (2023) · Cells · doi:10.3390/cells13010079 · Cited by 58
Zheng, Y., Zhang, X., Wang, Z., Zhang, R., Wei, H., Xu, Y., Jiang, X., & Yang, L. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400459 · Cited by 61
Martinez, E. M., Young, A. L., Patankar, Y. R., Berwin, B. L., Wang, L., von Herrmann, K. M., Weier, J. M., & Havrda, M. C. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx117 · Cited by 59
Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?
Mason, A., Holmes, C., & Edwards, C. J. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.001 · Cited by 59
Châlons, P., Amor, S., Courtaut, F., Cantos‐Villar, E., Richard, T., Auger, C., Chabert, P., Schini‐Kerth, V. B., Aires, V., & Delmas, D. (2018) · Nutrients · doi:10.3390/nu10121856 · Cited by 58
Wang, Y., Zhu, T., Wang, M., Zhang, F., Zhang, G., Zhao, J., Zhang, Y., Wu, E., & Li, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00291 · Cited by 58
Liu, M., Guo, H. W., Li, Z., Zhang, C., Zhang, X., Cui, Q., & Tian, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.601603 · Cited by 57
Qiu, X., Wang, Q., Hou, L., Zhang, C., Wang, Q., & Zhao, X. (2021) · Toxicology Letters · doi:10.1016/j.toxlet.2021.05.008 · Cited by 59
Liu, Z., Wang, C., & Lin, C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121498 · Cited by 57
Zhang, D., Zhang, Y., Pan, J., Cao, J., Sun, X., Li, X., Zhang, L., & Qin, C. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14219 · Cited by 59
Serum Amyloid A Induces NLRP-3-Mediated IL-1β Secretion in Neutrophils
Migita, K., Izumi, Y., Jiuchi, Y., Kozuru, H., Kawahara, C., Nakamura, M., Nakamura, T., Agematsu, K., Masumoto, J., Yasunami, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096703 · Cited by 57
NLRP3 Promotes Glioma Cell Proliferation and Invasion via the Interleukin-1β/NF-κB p65 Signals
Xue, L., Lu, B., Gao, B., Shi, Y., Xu, J.-Q., Yang, R., Xu, B. L., & Ding, P. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15264647024196 · Cited by 58
Hung, W., Ho, C., & Pan, M. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900550 · Cited by 57
Atluri, V. S. R., Tiwari, S., Rodriguez, M., Kaushik, A. K., Yndart, A., Kolishetti, N., Yatham, M., & Nair, M. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00342 · Cited by 62
The involvement of NLRP3 inflammasome in the treatment of neurodegenerative diseases
Feng, Y.-S., Tan, Z., Wu, L., Dong, F., & Zhang, F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111428 · Cited by 59
Primiani, C. T., Ryan, V. H., Rao, J. S., Cam, M. C., Ahn, K., Modi, H. R., & Rapoport, S. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110972 · Cited by 56
Inflammasomes and Cell Death: Common Pathways in Microparticle Diseases
Rashidi, M., Wicks, I. P., & Vince, J. E. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.06.005 · Cited by 58
Tang, Y., Dong, X., Chen, G., Ye, W., Kang, J., Tang, Y., & Feng, Z. (2020) · Neurorehabilitation and neural repair · doi:10.1177/1545968320948065 · Cited by 56
Wu, Y., Teng, Y., Zhang, C., Pan, Y. H., Zhang, Q., Zhu, X. H., Liu, N., Su, X., & Lin, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01320-0 · Cited by 56
The Role of Epigenetics in Neuroinflammatory-Driven Diseases
Giallongo, S., Longhitano, L., Denaro, S., D’Aprile, S., Torrisi, F., Spina, E. L., Giallongo, C., Mannino, G., Furno, D. L., Zappalà, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315218 · Cited by 62
Kumari, S., Dhapola, R., Sharma, P., Singh, S. K., & HariKrishnaReddy, D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102098 · Cited by 58
Exercise mimetics: a novel strategy to combat neuroinflammation and Alzheimer’s disease
Zhao, R. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03031-9 · Cited by 64
Lerose, V., Ponticelli, M., Benedetto, N., Carlucci, V., Lela, L., Tzvetkov, N. T., & Milella, L. (2024) · Plants · doi:10.3390/plants13060771 · Cited by 66
Song, Z., Xie, X., Chen, Y., Zhang, B., Li, X., Yang, Y., Mo, W., Zhang, J., & Xu, D. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.024 · Cited by 62
Galectins and Neuroinflammation
Chen, H.-L., Liao, F., Lin, T., & Liu, F. (2014) · Advances in neurobiology · doi:10.1007/978-1-4939-1154-7_24 · Cited by 58
From dysfunctional endoplasmic reticulum-mitochondria coupling to neurodegeneration
Erpapazoglou, Z., Mouton‐Liger, F., & Corti, O. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.03.021 · Cited by 59
Role of pattern recognition receptors of the neurovascular unit in inflamm-aging
Wilhelm, I., Nyúl-Tóth, Á., Kozma, M., Farkas, A. E., & Krizbai, I. A. (2017) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00106.2017 · Cited by 56
Metadata
- Authors
- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., Latz, E., & Golenbock, D. T.
- Affiliations
- University of Bonn (DE)
- Technische Universität Braunschweig (DE)
- University of Massachusetts Chan Medical School (US)
- Center of Advanced European Studies and Research (DE)
- Corresponding author
- Heneka, Michael T.
- Latz, Eicke
- Golenbock, Douglas T.
- ORCID
- Venue
- Nature
- Published
- 2012-12-19
- Volume
- 493
- Issue
- 7434
- Pages
- 674-678
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3812809
- OpenAlex
- W1993976394
- Semantic Scholar
- 3a962c33176c94bc0dd8bfea4ebe2eb83be8a01e
- Cited by
- 2,898
- References
- 34
- Citations by year
- 2026: 274 · 2025: 270 · 2024: 273 · 2023: 270 · 2022: 306 · 2021: 314 · 2020: 261 · 2019: 203 · 2018: 187 · 2017: 147 · 2016: 117 · 2015: 112 · 2014: 99 · 2013: 62
- FWCI
- 35.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- DZNE Pub (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute (R01HL093262)
- National Institute of General Medical Sciences (R01GM054060)
- National Institute of Allergy and Infectious Diseases (U19AI084048, R01AI083713)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- NLRP3 inflammasome, caspase-1, Alzheimer's disease, amyloid-beta, APP/PS1 mice, microglia, neuroinflammation, IL-1β, amyloid-beta clearance, spatial memory, NLRP3 knockout mice, cognitive impairment, therapeutic target
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Aged, Aged, 80 and over, Alzheimer Disease, Animals, Behavior, Animal, Brain, Carrier Proteins, Humans, Memory, Mice, Inbred C57BL, Mice, Transgenic, Phagocytosis, Gene Expression Regulation, Enzymologic, Amyloid beta-Peptides, Caspase 1, Mice, Nitric Oxide Synthase Type II, Interleukin-1beta, Inflammasomes, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
